Date Filer Title Filing Type Shares Traded Price Total Held
December 11, 2023 Chief Medical Officer Form 3 Initial Statement of Beneficial Ownership of Securities -- -- --
December 7, 2023 Chief Medical Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 -- 20,000
December 7, 2023 Chief Medical Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 80,000 -- 80,000
March 17, 2023 Chief Scientific Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 40,000 -- 85,688
March 17, 2023 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,000 -- 16,430
March 17, 2023 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,000 -- 18,429
March 17, 2023 CFO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 40,000 -- 95,950
March 17, 2023 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,000 -- 4,667
March 17, 2023 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,000 -- 30,099
March 17, 2023 Director, President and CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 90,000 -- 320,000
March 17, 2023 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,000 -- 9,666
March 17, 2023 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,000 -- 9,666
March 17, 2023 Director, Executive Chairman of Board Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 25,000 -- 215,846
October 3, 2022 Director Form 3 Initial Statement of Beneficial Ownership of Securities -- -- --
September 30, 2022 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,667 -- 2,667
July 20, 2022 Director, President and CEO Form 3 Initial Statement of Beneficial Ownership of Securities -- -- --
July 18, 2022 Director, President and CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 53,000 -- 53,000
July 18, 2022 Director, President and CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 177,000 -- 177,000
June 13, 2022 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 6,250 -- 22,587
June 13, 2022 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 7,500 -- 27,242
June 13, 2022 CFO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 50,000 -- 97,659
June 13, 2022 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 7,500 -- 27,004
June 13, 2022 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 7,500 -- 26,978
June 13, 2022 Chief Accounting Officer Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 1,750 -- 5,833
June 13, 2022 Director Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 2,500 -- 7,666

For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.